With respect to exosome testing, PPHM has published "Highly Specific PET Imaging of Prostate Tumors in Mice with an Iodine-124-Labeled Antibody Fragment That Targets Phosphatidylserine."
Images of tumor location show clearly in a PET scan. Any metastases should also be evident in a scan.
Exosome test tells doctors/patients that there is a significant quantum of PS-positive exosomes in the patient's system. The next step would be a conformational and locational scan.
Peregrine ran a human trial at Washington University School of Medicine, started June 2012, and closed out on schedule, March 2016. Peregrine has that data.
"Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors"
The high value of the "Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies" is the ability to diagnose this ovarian tumor type at an earlier stage than has been previously possible. It should be a real lifesaver for many women in the future of ovarian oncology.